Skyhawk Therapeutics Announces Strategic Collaboration with Merck to Discover Novel RNA-Targeting Small Molecules for Neurological Disorders

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Skyhawk-Merck-collab

More Like This

PR Newswire associated0

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

PR Newswire associated0

Skyhawk Therapeutics Expands into State-of-the-Art Labs in its Basel, Switzerland Location

Skyhawk Therapeutics Receives HREC Approval for a Phase 1 Study of its SKY-0515 RNA-Targeting Small Molecule for Huntington's Disease

PR Newswire associated0

Skyhawk Therapeutics Has Advanced to the Multiple Ascending Dose Portion of its Phase 1 Study evaluating SKY-0515, a RNA-Targeting Small Molecule for Huntington's Disease

PR Newswire associated0

Skyhawk Therapeutics Presents at Huntington's Disease Youth Organization HDYO International Congress 2025

PR Newswire associated0

Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease

Shanghai Argo Announces Multi-Program RNAi Licenses and Strategic Collaborations with Novartis

PR Newswire associated0

Servier and Base4 Expand Partnership to Advance Neuroscience Drug Development